Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Pemvidutide, an investigational dual-pathway therapy, demonstrates sustained metabolic improvements across liver function, lipid profiles, and cardiovascular risk markers in a 48-week Phase 2b trial. The data suggest a mechanistic advantage over single-pathway GLP-1 agents by addressing the interconnected metabolic dysfunction underlying fatty liver disease and cardiovascular risk.
Traditional risk factors—age, sex, smoking, alcohol consumption, waist-to-hip ratio, and BMI—predict chronic disease incidence more accurately than epigenetic clocks in middle-aged adults over 7–9 years. This finding challenges the clinical utility of epigenetic aging biomarkers without demonstrated incremental value over conventional assessment.
Haut.AI has launched an AI-powered platform that analyzes skin across the entire body—not just the face—to provide quantitative measurements and personalized product recommendations. The technology was trained on over 100,000 skin images across all skin types and validated for clinical accuracy, addressing a market gap where 80% of consumers report pressure to maintain healthy-looking skin.
Current UK health guidelines establish bare-minimum thresholds for physical activity and protein intake designed to prevent deficiency, not optimize healthspan. Evidence demonstrates substantially higher levels of activity and protein consumption correlate with meaningfully reduced mortality risk and preserved physical independence across the lifespan.
Helix and AstraZeneca established a multi-year partnership granting access to GenoSphere cohorts—genomic datasets paired with longitudinal clinical records spanning 13 years—to accelerate drug discovery across cardiometabolic, respiratory, and autoimmune conditions. This arrangement represents a shift toward precision-medicine-informed development pipelines that integrate genotype with documented clinical outcomes.
HRS-7535, an oral GLP-1 receptor agonist, demonstrated 11.1% weight loss at 44 weeks in Phase 3 trials with a favorable safety profile dominated by mild-to-moderate gastrointestinal effects. The drug also showed non-inferiority to dapagliflozin in type 2 diabetes management while producing larger HbA1c reductions, positioning it as an alternative to injectable agents in metabolic disease treatment.
BioAge has initiated Phase 2 testing of BGE-102, an NLRP3 inflammasome inhibitor, to assess whether reducing systemic inflammation improves cardiovascular outcomes in adults at elevated risk. The trial represents a shift in drug discovery methodology—identifying therapeutic targets through analysis of successful aging biology rather than disease pathology—potentially targeting a shared mechanism underlying multiple age-related conditions.
Valiltramiprosate, an oral agent from Alzheon, demonstrates neurovascular protection and preservation of hippocampal structure in extended analyses of phase 3 and biomarker studies, with clinically meaningful cognitive benefits observed in mild cognitive impairment subgroups despite the primary endpoint not being met. The data suggest potential utility as maintenance therapy following anti-amyloid interventions, particularly for apoE4 carriers at elevated risk for cerebral amyloid angiopathy.
Rural older adults in Korea engage in significantly less moderate-intensity physical activity than urban counterparts, driven by differences in healthcare access, transportation, and social infrastructure rather than health status alone. This disparity represents a modifiable risk factor for accelerated aging and reduced healthspan in underserved populations.
MuseCell Innovations has launched Dezawa MuseCells in the United States, offering a validated pluripotent-like cell therapy that combines active tissue-homing capability with intrinsic immune tolerance. This domestic availability eliminates the need for overseas treatment while addressing longstanding safety and efficacy gaps in the regenerative medicine market.
Pemvidutide, a dual glucagon/GLP-1 receptor agonist, demonstrated sustained reductions in cardiometabolic risk factors and liver fibrosis over 48 weeks in patients with metabolic dysfunction-associated steatohepatitis. This positions the compound as a potential therapeutic option in a therapeutic area where metabolic and hepatic dysfunction often progress in parallel.
Sky Labs' cuffless blood pressure ring (CART BP pro) has been adopted for a large-scale NIH-managed cohort study in South Korea, addressing a critical gap in continuous vital sign monitoring. The device eliminates the sleep disruption and compliance failures inherent to traditional 24-hour ambulatory blood pressure monitors, enabling sustained data collection without the physiological and behavioral burden of repeated arm constriction.